Cargando…
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
Proprotein convertase subtilisin kexin 9 (PCSK-9)-targeting therapy has arisen as a new line for the treatment of hyperlipidemia. Inclisiran is a double-stranded small RNA molecule that works by blocking the transcription of PCSK-9, leading to a reduction of PCSK9 levels in the hepatocytes, resultin...
Autores principales: | Kosmas, Constantine E, Muñoz Estrella, Alba, Skavdis, Andreas, Peña Genao, Edilberto, Martinez, Ian, Guzman, Eliscer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604242/ https://www.ncbi.nlm.nih.gov/pubmed/33149595 http://dx.doi.org/10.2147/TCRM.S230592 |
Ejemplares similares
-
Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018) -
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas, Constantine E, et al.
Publicado: (2020) -
The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease
por: Kosmas, Constantine E., et al.
Publicado: (2023) -
Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2022) -
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2019)